Konstantin Adamsky
Director/Board Member bei FILAMENT HEALTH CORP.
Profil
Konstantin Adamsky is currently the Chief Executive Officer at Negev Labs and an Independent Director at Filament Health Corp.
He previously worked as the Co-Chief Executive Officer & Director at Targia Pharmaceuticals Ltd.
in 2016, Vice President-Operations at Regenera Pharma Ltd.
from 2017 to 2020, and as VP Operations & Technology at Levco Pharmaceuticals Ltd.
He holds a doctorate degree from the Weizmann Institute of Science.
Aktive Positionen von Konstantin Adamsky
| Unternehmen | Position | Beginn |
|---|---|---|
| FILAMENT HEALTH CORP. | Director/Board Member | 23.08.2022 |
Ehemalige bekannte Positionen von Konstantin Adamsky
| Unternehmen | Position | Ende |
|---|---|---|
Regenera Pharma Ltd.
 Regenera Pharma Ltd. Pharmaceuticals: MajorHealth Technology Regenera Pharma Ltd. develops a novel drug candidate, RPH201 for neurological indications. It also focuses on developing a treatment for Nonarteritic Anterior Ischemic Optic Neuropathy (NAION), the most common cause of sudden optic nerve-related vison loss in older people. The company is headquartered in Ness-Ziona, Israel. | Chief Executive Officer | 01.08.2017 |
| Levco Pharmaceuticals Ltd. | Chief Operating Officer | - |
Ausbildung von Konstantin Adamsky
| Weizmann Institute of Science | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| FILAMENT HEALTH CORP. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Regenera Pharma Ltd.
Regenera Pharma Ltd. Pharmaceuticals: MajorHealth Technology Regenera Pharma Ltd. develops a novel drug candidate, RPH201 for neurological indications. It also focuses on developing a treatment for Nonarteritic Anterior Ischemic Optic Neuropathy (NAION), the most common cause of sudden optic nerve-related vison loss in older people. The company is headquartered in Ness-Ziona, Israel. | Health Technology |
| Levco Pharmaceuticals Ltd. |
